** Drug developer Disc Medicine's IRON.O shares fall ~5% to $59.46
** Company says in filing it expects to report material weakness in its internal control over financial reporting for year ending Dec. 31, 2024
** Disc Medicine adds issue due to ineffective Information Technology General Controls (ITGC) - policies aimed at keeping the company's IT systems secure and working properly - over some key financial IT systems
** Company says no misstatements have been identified in its financial statements so far
** Disc Medicine says its auditor has not completed the audit of its internal controls and cannot provide an opinion yet
** All 11 brokerages rate the stock "buy" or higher; median PT $90 - LSEG
** Company's shares gained 6.1% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。